Retatrutide + Cagrilintide
Retatrutide + Cagrilintide
$ 118
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, studied in Phase 2/3 obesity and MASLD trials with weight-loss results exceeding single/dual agonists. Paired here with cagrilintide (long-acting amylin receptor agonist) for combined appetite/metabolic research.
Benefits
✓ Potentially the most powerful weight loss combination
✓ Multi-pathway appetite and energy regulation
✓ GLP-1 + GIP + Glucagon + Amylin receptor engagement
✓ Rapid and sustained fat loss
✓ Improved metabolic health markers
✓ Multi-pathway appetite and energy regulation
✓ GLP-1 + GIP + Glucagon + Amylin receptor engagement
✓ Rapid and sustained fat loss
✓ Improved metabolic health markers
Side Effects
• Compounded GI side effects (nausea, vomiting, diarrhea)
• Significant appetite suppression
• Injection site reactions
• Risk of excessive weight loss and lean mass reduction
• Very limited human safety data in combination
• Significant appetite suppression
• Injection site reactions
• Risk of excessive weight loss and lean mass reduction
• Very limited human safety data in combination
Half Life
Retatrutide: ~6 days / Cagrilintide: ~7 days
Note
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Composition and dosing ratios are vendor-defined and not independently verified.
Retatrutide + Cagrilintide
$ 118
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, studied in Phase 2/3 obesity and MASLD trials with weight-loss results exceeding single/dual agonists. Paired here with cagrilintide (long-acting amylin receptor agonist) for combined appetite/metabolic research.
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Composition and dosing ratios are vendor-defined and not independently verified.
✓ Potentially the most powerful weight loss combination
✓ Multi-pathway appetite and energy regulation
✓ GLP-1 + GIP + Glucagon + Amylin receptor engagement
✓ Rapid and sustained fat loss
✓ Improved metabolic health markers
✓ Multi-pathway appetite and energy regulation
✓ GLP-1 + GIP + Glucagon + Amylin receptor engagement
✓ Rapid and sustained fat loss
✓ Improved metabolic health markers
Retatrutide: ~6 days / Cagrilintide: ~7 days
